LKT Laboratories, Inc.

Naftopidil

Phone: 888-558-5227
651-644-8424
Fax: 888-558-7329
Email: getinfo@lktlabs.com
Web: lktlabs.com

Product Information

Product ID N0123
CAS No. 57149-07-2
Chemical Name

Synonym

Formula $C_{24}H_{28}N_2O_3$
Formula Wt. 392.49
Melting Point 209.0 - 212.0
Purity ≥98%
Solubility



Bulk quanitites available upon request

Product ID	Size
N0123	25 mg
N0123	100 mg
N0123	500 mg

Store Temp Ambient
Ship Temp Ambient

Description Naftopidil is an inhibitor of α1-adrenergic receptors that is clinically used to improve lower urinary tract symptoms in subjects with benign prostatic hyperplasia (BPH). In clinical trials, naftopidil improves nocturnal polyuria. Naftopidil improves bladder capacity through both its effect on adrenergic signaling as well as inhibition of c-fiber afferent nerves. Additionally, this compound inhibits collagen-induced Ca2+ mobilization and platelet aggregation in vitro, exhibiting potential anti-platelet benefit.

References

Castiglione F, Benigni F, Briganti A, et al. Naftopidil for the treatment of benign prostate hyperplasia: a systematic review. Curr Med Res Opin. 2013 Dec 18. [Epub ahead of print]. PMID: 24188134.

Yokoyama O, Aoki Y, Tsujimura A, et al. α(1)-adrenoceptor blocker naftopidil improves sleep disturbance with reduction in nocturnal urine volume. World J Urol. 2011 Apr;29(2):233-8. PMID: 20387069.

Yokoyama O, Yusup A, Oyama N, et al. Improvement of bladder storage function by alpha1-blocker depends on the suppression of C-fiber afferent activity in rats. Neurourol Urodyn. 2006;25(5):461-7. PMID: 16673377.

Alarayyed NA, Cooper MB, Prichard BN, et al. In vitro adrenaline and collagen-induced mobilization of platelet calcium and its inhibition by naftopidil, doxazosin and nifedipine. Br J Clin Pharmacol. 1997 Apr;43(4):415-20. PMID: 9146854.